IL-5
IL-5 Informations sur la molécule
| Nom anglais | Interleukin-5 | Nombre de médicaments commercialisés | 3 |
| Nombre de médicaments cliniques | 6 | Alias de la cible | T-cell replacing factor，IL5，Interleukin 5，Eosinophil Differentiation Factor，Colony-Stimulating Factor， Eosinophil，B-Cell Differentiation Factor I，Interleukin-5，IL-5，TRF，Interleukin 5 (Colony-Stimulating Factor， Eosinophil)，B Cell Differentiation Factor I，EDF |
| Phase de R&D la plus avancée | Approved | ||
| Nom anglais | Interleukin-5 |
| Alias de la cible | T-cell replacing factor，IL5，Interleukin 5，Eosinophil Differentiation Factor，Colony-Stimulating Factor， Eosinophil，B-Cell Differentiation Factor I，Interleukin-5，IL-5，TRF，Interleukin 5 (Colony-Stimulating Factor， Eosinophil)，B Cell Differentiation Factor I，EDF |
| Nombre de médicaments commercialisés | 3 |
| Nombre de médicaments cliniques | 6 |
| Phase de R&D la plus avancée | Approved |
IL-5 Liste de produits
- Attribut
Protein (8)Kits (2)
- Bibliothèque de produits
En ligne (10)
- Espèces
Human (5)Rabbit (1)Mouse (1)Cynomolgus (1)Canine (1)Rat (1)
- Étiquette
His Tag (6)His Tag & Avi Tag (1)- (2)Tag Free (1)
- Marqueur
Unconjugated (7)Biotin-labeled (1)- (2)
| Numéro de produit | Espèces | Système d'expression | Description du produit | Structure protéique | Pureté | Caractéristiques | Pré-commande/Commande |
|---|---|---|---|---|---|---|---|
 Human | HEK293 | Human IL-5 Protein, His Tag |  |  |  |  Ajouter au panier | |
| Human | HEK293 | Biotinylated Human IL-5 Protein, His,Avitag™ (MALS verified) |  | | | Ajouter au panier | |
HOT IL5-C52H3 |  Cynomolgus | HEK293 | Cynomolgus IL-5 Protein, His Tag, low endotoxin |  | | | Ajouter au panier |
HOT IL5-R52H4 |  Rabbit | HEK293 | Rabbit IL-5 Protein, His Tag |  | | | Ajouter au panier |
| Human | - | Human IL-5 ELISA Kit | Ajouter au panier | ||||
| Human | - | IL-5 [Biotinylated] : IL-5Rα Inhibitor Screening ELISA Kit | Ajouter au panier | ||||
| Human | HEK293 | Human IL-5 Protein, premium grade |  | |  | Ajouter au panier | |
 Mouse | HEK293 | Mouse IL-5 Protein, His Tag (MALS verified) |  | | | Ajouter au panier | |
 Canine | HEK293 | Canine IL-5 Protein, His Tag (MALS verified) |  | | | Ajouter au panier | |
 Rat | HEK293 | Rat IL-5 Protein, His Tag (MALS verified) |  | | | Ajouter au panier |
Quantité totale10
- 1
IL-5Contexte de la molécule
Interleukin 5 (IL5) is an interleukin produced by type-2 T helper cells and mast cells. IL-5 is a 115-amino acid (in human, 133 in the mouse) -long TH2 cytokine that is part of the hematopoietic family. Unlike other members of this cytokine family (namely interleukin 3 and GM-CSF), this glycoprotein in its active form is a homodimer. Interleukin-5 has long been associated with the cause of several allergic diseases including allergic rhinitis and asthma, wherein a large increase in the number of circulating, airway tissue, and induced sputum eosinophils have been observed. Given the high concordance of eosinophils and, in particular, allergic asthma pathology, it has been widely speculated that eosinophils have an important role in the pathology of this disease. Drugs that target IL-5 are mepolizumab and reslizumab.
IL-5Alias de la molécule
IL-5,TRF,IL5,Interleukin-5
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian) | 610; SSGJ-610 | Phase 3 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Asthma; Autoimmune Diseases | Details |
| SHR-1703 | SHR-1703 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Asthma; Eosinophilic Asthma; Eosinophilic Granulomatosis With Polyangiitis | Details |
| RC-1416 | RC14/16; RC-1416 | Phase 2 Clinical | Nanjing RegeneCore Biotech Co Ltd | Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive | Details |
| long-acting anti-IL-5 mAb (GSK) | Phase 1 Clinical | Glaxosmithkline Plc | Asthma | Details | |
| Mepolizumab biosimilar(Bio Thera Solutions) | BAT2606; BAT-2606 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Asthma; Autoimmune Diseases; Nasal Polyps; Sinusitis | Details |
| Mepolizumab biosimilar (CTTQ Pharma) | TQC-3566; TQC3566 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Asthma; Eosinophilic Granuloma; Eosinophilic Granulomatosis With Polyangiitis; Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Lymphohistiocytosis, Hemophagocytic; Nasal Polyps; Sinusitis; Vasculitis | Details |
Informations sur les médicaments commercialisés
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Plus ancien nom de marque | Pays d'approbation le plus ancien | Indication la plus ancienne | Société d'approbation la plus ancienne | Date d'approbation la plus ancienne | Indication | Essai clinique |
|---|---|---|---|---|---|---|---|---|---|---|
| Reslizumab | CEP-38072; SCH-5570; TRFK-5; SCH-55700; CDP-835; CTx-55700 | Approved | Teva Pharmaceutical Industries Ltd | Cinquil, Cinqair, Cinqaero | United States | Asthma | Teva Respiratory Llc | 2016-03-23 | Asthma; Bronchitis; Eosinophilic Esophagitis; Hypereosinophilic Syndrome; Loiasis; Pulmonary Eosinophilia | Details |
| Depemokimab | GSK-3511294; AQ82742999; GSK3511294; GSK-294; GSK294 | Approved | Glaxosmithkline Plc | 易适来, Exdensur | United Kingdom | Asthma; Sinusitis; Nasal Polyps | Glaxosmithkline Plc | 2025-12-15 | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Eosinophilic Asthma; Eosinophilic Granuloma; Eosinophilic Granulomatosis With Polyangiitis; Hypereosinophilic Syndrome; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis; Vasculitis | Details |
| Mepolizumab | SB-240563; 240563 | Approved | Glaxosmithkline Plc | Bosatria, Nucala, 美泊利珠单抗, 新可来 | United States | Asthma | Glaxosmithkline Llc | 2015-11-04 | Angioedema; Asthma; Bronchitis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Eosinophilia; Eosinophilic Esophagitis; Eosinophilic Granulomatosis With Polyangiitis; Fasciitis; Granulomatosis with Polyangiitis; Hypereosinophilic Syndrome; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis; Virus Diseases | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments commercialisés
- Informations sur les médicaments cliniques